In addition to hypomethylating agents, treatments targeting genetic features of the malignant clone, such as FLT3 inhibitors (FLT3 mutated AML) and IDH1/IDH2 inhibitors (IDH1/IDH2 mutant AML) are under development or in clinical use [83]. Here, IDH2 is linked to acute myeloid leukemia.